Literature DB >> 83910

Serum acute-phase proteins and immunoglobulins in patients with gliomas.

J F Weiss, R A Morantz, W P Bradley, P B Chretien.   

Abstract

Cellular immune competence was found to be impaired in previous studies of patients with malignant brain tumors. In patients with nonneural tumors, we recently found that serum levels of acute-phase proteins were related to immune status as well as to tumor extent. To determine whether the serum proteins in patients with central nervous system tumors show similar changes, levels of acute-phase proteins (alpha1-acid glycoprotein, alpha1-antitrypsin, haptoglobin, C-reactive protein) and immunoglobulins (immunoglobulins G, M, and A) were assayed in patients with gliomas prior to treatment. Compared to normals, significant increases (p less than 0.001) in the acute-phase proteins were found, and the levels were similar to those in patients with nonneural solid neoplasms. Serum immunoglobulins were not significantly increased in patients with gliomas.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 83910

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Efficacy of local delivery of ardipusilloside I using biodegradable implants against cerebral tumor growth.

Authors:  Huan Dang; Ji Wang; Jiang-Xue Cheng; Peng-Yuan Wang; Ying Wang; Li-Fei Cheng; Caigan Du; Xiao-Juan Wang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 2.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 4.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

5.  Immunosuppressive acidic protein in patients with brain tumours: a preliminary report.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

6.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Binding of vinblastine to recrystallized human alpha 1-acid glycoprotein.

Authors:  W H Steele; D J Haughton; H E Barber
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

8.  A correlation between serum immunosuppressive acidic protein and altered immunocompetence in patients with brain tumours.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

9.  Prognostic significance of serum alpha 1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication.

Authors:  H Matsuura; S Nakazawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

10.  Serum albumin and survival in glioblastoma multiforme.

Authors:  Nicholas Borg; Mathew R Guilfoyle; David C Greenberg; Colin Watts; Simon Thomson
Journal:  J Neurooncol       Date:  2011-03-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.